Related Experiment Videos
Percutaneous ablation therapy for hepatocellular carcinoma: current practice and future perspectives
Teh-Ia Huo1, Yi-Hsiang Huang, Jaw-Ching Wu
1National Yang-Ming University School of Medicine, Taiwan, ROC. tihuo@vghtpe.gov.tw
Journal of the Chinese Medical Association : JCMA
|April 27, 2005
Summary
Hepatocellular carcinoma (HCC) treatments like ablation are effective for unresectable tumors. A tailored, multimodal approach is recommended for better outcomes in HCC patients.
Area of Science:
- Hepatobiliary Oncology
- Interventional Radiology
Background:
- Hepatocellular carcinoma (HCC) is a prevalent and challenging malignancy.
- Surgical resection is limited due to hepatic reserve and tumor characteristics.
- Percutaneous ablation therapies have become primary treatments for unresectable HCC.
Purpose of the Study:
- To review current percutaneous ablation therapies for unresectable HCC.
- To evaluate the efficacy and limitations of various ablation techniques.
- To discuss the potential for multimodal and tailored therapeutic strategies.
Main Methods:
- Review of percutaneous ablation therapies including PEI, PAI, RFA, and MCT.
- Discussion of combination approaches with transcatheter arterial embolization.
- Consideration of less common ablation modalities.
Main Results:
- PEI and PAI are effective for small HCC (<3 cm), with PAI requiring fewer sessions.
- RFA offers predictable tumor necrosis but may have a higher complication rate.
- MCT shares similarities with RFA in application and adverse effects.
- Combination therapy is effective for large HCC.
Conclusions:
- Current percutaneous ablation therapies offer options for unresectable HCC.
- A multimodal, image-guided, tailored approach may be superior to fixed algorithms.
- Improved efficacy of novel anti-tumor therapies is needed for better HCC prognosis.